|
J Biol Chem, Vol. 273, Issue 8, 4360-4366, February 20, 1998
Hormone-induced Recruitment of Sp1 Mediates Estrogen Activation
of the Rabbit Uteroglobin Gene in Endometrial Epithelium*
Axel
Scholz ,
Mathias
Truss, and
Miguel
Beato§
From the Institut für Molekularbiologie und Tumorforschung,
Philipps-Universität, Emil-Mannkopff-Straße 2, D-35037 Marburg, Germany
 |
ABSTRACT |
Steroid hormones activate gene expression by
interaction of their receptors with hormone-responsive DNA elements and
tissue-specific or ubiquitous factors. To monitor the molecular changes
on the promoter of the rabbit uteroglobin gene during early
pseudopregnancy in vivo, we have applied the genomic
footprinting methodology to endometrial tissue. Estrogen induction
results in the simultaneous occupancy of an estrogen-responsive element
and an adjacent GC/GT box in the promoter. DNA binding assays
demonstrate that the corresponding regulatory factors are the
ligand-induced estrogen receptor and the ubiquitous transcription
factor Sp1. Both factors functionally synergize in primary endometrial
cells, showing that the GC/GT box is an essential part of a composite
estrogen-responsive unit. However, the estrogen receptor and Sp1 do not
bind cooperatively to their sites in vitro, suggesting that
other mechanisms might be responsible for the
hormone-dependent binding of Sp1 in vivo. Since
hormone treatment leads to the appearance of a distinct DNase
I-hypersensitive site over the promoter chromatin, an estrogen-induced change in the local chromatin structure could facilitate binding of Sp1
in vivo.
 |
INTRODUCTION |
Gene expression is controlled by combinatorial arrangement of
sequence-specific transcription factors that interact with each other
and with components of the transcription initiation complex. Modulation
of gene transcription is achieved by factors whose activity is
reversibly influenced by ligands or posttranslational modifications, such as phosphorylation. The transcriptional effects of
ligand-inducible steroid hormone receptors represent a typical example.
To attain efficiency and specificity in gene regulation, steroid
hormone receptors interact with ubiquitous or tissue-specific factors
as well as with co-activators, which bridge to the general transcriptional apparatus (1).
The particular combination of factors and the nature of the
interactions required for regulated expression of a gene is specified in the form of complex arrays of cis-acting elements in its
enhancer and promoter regions. These elements are usually identified
through gene transfer experiments and in vitro DNA binding
studies. However, the binding of factors to cognate DNA elements, as
well as interactions with other factors, is conditioned by the native
organization of DNA in chromatin, which imposes defined topological
constraints (2). Therefore, demonstration of the functional relevance
of DNA elements requires a genomic analysis of the chromosomally organized gene in intact cells.
To approach these issues, we have studied the steroid
hormone-dependent regulation of the rabbit uteroglobin
gene. In female animals, the gene is transcriptionally active in
epithelial cells of the endometrium during the preimplantation phase of
pregnancy (3, 4). Estrogen and progesterone exert a stimulatory effect on transcription (5). Whereas the action of progesterone is probably
mediated by an upstream enhancer region containing two clusters of
progesterone receptor binding sites (6), estrogen might function via a
noncanonical estrogen-responsive element (ERE),1 as suggested by gene
transfer and in vitro binding assays (7).
We have analyzed the promoter of the endogenous uteroglobin gene by
genomic footprinting in endometrial epithelium from uterus in
situ. Upon hormone treatment, we detect endometrium-specific occupancy of the noncanonical ERE in the promoter. Concomitantly, we
observe estrogen-dependent recruitment of Sp1 to an
adjacent site, which proved to be functionally essential for estrogen
induction of the promoter. We provide evidence that Sp1 but not the
related transcription factor Sp3 (8) mediates estrogen induction.
Within this composite unit, the estrogen receptor (ER) and Sp1 bind
noncooperatively in vitro. Synergistic binding in
vivo could involve the chromatin configuration of DNA, since
estrogen treatment induces a change in the chromatin structure of the
promoter documented by the appearance of a prominent DNase
I-hypersensitive site.
 |
EXPERIMENTAL PROCEDURES |
Plasmids--
For the construction of the uteroglobin
promoter-driven luciferase reporter plasmid, a HindIII
( 395) to XhoI (+14) uteroglobin promoter fragment (9) was
inserted into the pXP2 plasmid (10). Promoter linker-scanner mutants
were generated from similar constructs (9). Further mutations were
introduced by oligonucleotide-directed mutagenesis (11). The following
expression plasmids for insect cells were used: for the expression of
OctI, pPacOct (kindly supplied by C. Möws (12)); for human ER
(13), pPacER (constructed and provided by G. Suske); for Sp1, pPacSp1
(14); and for Sp3, pPacUbxSp3 (15).
Genomic Dimethyl Sulfate (DMS) Footprinting in Vivo and
Ligation-mediated Polymerase Chain Reaction--
DMS footprinting was
performed according to Ref. 16. In brief, endometrial epithelium or
liver cells were exposed to 0.2% DMS in Dulbecco's modified Eagle's
medium for 5 min. The reaction was stopped by washing several times
with phosphate-buffered saline. Epithelial cells were separated, and
genomic DNA was prepared, cleaved with piperidine, and submitted to a
ligation-mediated polymerase chain reaction as described (17). The
following gene-specific oligonucleotides were used: for the upper
strand, ERA1 (GATCCTGGGTGCTCCT), ERA2 (TCACAGCCACTTGGGCCTCAGC), and
ERA3 (GGCCTCAGCTTCTCCTGTGACAGG); for the lower strand, ER1
(ACTGCATTATTTACTTGGG), ER2 (CATTGACTTGGTGGGATAAGTAAATATTCCC), and ER3
(TTCCCTTTTCTCAATCCAGTTTCCATCCC).
Electrophoretic Mobility Shift Analysis (EMSA) and Methylation
Protection Analysis in Vitro--
Nuclear extracts for EMSA were
prepared according to Ref. 18. The following double-stranded DNA
oligonucleotides were used: GTI, named Sp, containing a uteroglobin
Sp-binding site ( 232 to 223) (8); a uteroglobin promoter
(Fnu4HI-HpaII) fragment comprising an ERE and
Sp-binding site ( 304 to 207) or the respective linker-scanner
mutants (9); and a consensus ERE (19). The gel-purified
oligonucleotides were 32P-labeled by the Klenow filling-in
reaction, and unincorporated nucleotides were removed through gel
filtration. Recombinant human ER was expressed in COS-7 cells by
transient transfection with the expression plasmid HEGO (13).
Antibodies against Sp1 (20) and ER (21) were preincubated with nuclear
extracts for 15 min at room temperature. Poly(dI-dC) and calf thymus
DNA were added as nonspecific competitor, and binding buffers were as
described in Ref. 22 but containing 3 mM ZnCl2.
The binding reaction was incubated at room temperature for 15 min
before loading on a 5% nondenaturing polyacrylamide gel.
10 7 M diethylstilbestrol was included in
experiments with ER. Gels were run in 0.5-fold Tris borate/EDTA buffer
at 7 V/cm and room temperature for 120 min, dried, and
autoradiographed.
Cell Transfection and Reporter Assay--
SL2 Schneider cells
were maintained in Schneider's modified Drosophila medium
supplemented with 10% fetal calf serum (insect cell-qualified, Life
Technologies, Inc.) at 25 °C. Transient transfections were performed
by the calcium phosphate method (23). A 60-mm dish received 5 µg of
reporter plasmid, different amounts of co-expression plasmids, and calf
thymus DNA to a total of 10 µg of DNA. Hormones were added directly
to the culture medium after 2.5 h of chloroquine treatment (0.1 mM). Anti-estrogen, ICI 164.384 (10 7
M), was eventually applied to noninduced cells to further
reduce basal reporter expression (24). Cells were harvested 48 h
after transfection, and extracts were prepared. Luciferase and
-galactosidase activity were determined as described (25) and
normalized to protein concentration, since co-expressed Sp
transcription factors might have affected standardization with an
internal reporter plasmid (26).
Animals and Treatments--
Adult 1/2- to 1-year-old
female New Zealand White or chinchilla bastard rabbits (3-4 kg) were
housed in individual cages under controlled conditions of temperature
and light (12 h light-dark) and were kept separated from male rabbits
to prevent pheromone-triggered ovulation. Pseudopregnancy was induced
by hCG (Ekluton, Vemie Veterinär Chemie, Kempen) injection (200 IU/kg of body weight) intramuscularly at day 0. Animals were killed at
day 4 by lethal injection of T61 (Hoechst, Germany) in the ear vein.
The uterus and liver were rapidly excised and rinsed in
phosphate-buffered saline.
Gene Transfer in Primary Cells--
Details of the method used
to isolate, cultivate, and transfect endometrial epithelium cells will
be published elsewhere. Briefly, the inner luminal surface of the
uterus was incubated with collagenase at 37 °C and flushed, and
cells were collected by centrifugation. The suspension of cells was
maintained in Dulbecco's modified Eagle's medium on polystyrene
culture dishes. The medium was supplemented with 5% newborn calf serum
(Life Technologies), penicillin (100 IU/ml), and streptomycin (100 µg/ml). Cells were cultivated at 37 °C in 5% CO2. The
purity of the primary cell preparation was determined by
immunocytochemistry employing an antibody against rabbit
uteroglobin.
Transient transfection was performed by the calcium phosphate
co-precipitation method (27). Hormones were added to the medium as
ethanolic solution immediately after transfection, and incubation was
continued for 48 h. Diethylstilbestrol was used as estrogen agonist, and ICI 164,384 (24) was used as as anti-estrogen. An
equivalent amount of solvent was used as control.
DNase I Hypersensitivity Analysis--
Treatment of cells with
DNase I was performed as described (17). 6 µg of genomic DNA were
cleaved with PvuII, resolved in 1.2% agarose gel, and
blotted on Biodyne A nylon membrane (Pall, Dreieich). Hybridization was
carried out with a radioactively labeled
(PvuII-BamHI) uteroglobin gene fragment (+193 to
+9) according to Ref. 28.
Quantitation of Radiolabeled DNA--
Quantitative evaluation
was performed directly from the dried gels applying phosphor screen
autoradiography using a PhosphorImager and ImageQuant software
(Molecular Dynamics Inc., Sunnyvale, CA) or from autoradiographs using
laser scanner and ScanPack software (Biometra, Göttingen).
 |
RESULTS |
Hormone-induced Changes in the Occupancy of Putative Regulatory
Elements--
Expression of the rabbit uteroglobin gene in epithelial
cells of the endometrium is induced by estrogen and progesterone (5). Using in vitro DNA binding experiments and transient gene
transfer, we have defined a noncanonical ERE located around 258 (7) and three Sp-binding sites (also referred to as GC/GT boxes) located around 225, 200, and 65, respectively (9, 29) (Fig.
1A). To determine the role of
these putative regulatory elements in hormone induction in
vivo, we have studied their occupancy by the genomic footprinting
technique (16). Since there are no suitable endometrial cell lines
available, we have applied the DMS footprinting technique to the rabbit
endometrial epithelium in situ after hormonal treatment of
the animal. Ligation-mediated polymerase chain reaction analysis of the
modified and piperidine-cleaved DNA revealed two
hormone-dependent footprints in the promoter region between
300 and 200, which appeared in the endometrial epithelium but not
in liver (Fig. 1B). Protection of three guanine residues
over the ERE was found in both strands (open triangles), whereas a hypermethylated guanine residue was found in the lower strand
(filled triangle). When compared with the liver lanes and taking as reference an unchanged band just upstream of the ERE, the
protection in the upper strand was 30% in average for the three
guanines. Over the adjacent GC/GT box, five guanine residues were
protected in the lower strand and a single guanine in the upper strand.
The corresponding residues are indicated in the nucleotide sequence of
Fig. 1A. The footprints were observed in the hormonally
induced endometrial epithelium but not in the uninduced endometrial
epithelium from oestrus female rabbits (Fig. 1C, and see
below). These footprints over the ERE and over the adjacent GC/GT box
never appeared singly but always pairwise after various hormonal
treatment leading to induction of the promoter. Interestingly, no
prominent footprints were observed over the other putative GC/GT boxes
located further proximally (data not shown).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 1.
DMS footprinting of the rabbit uteroglobin
promoter in vivo and in vitro. A,
schematic representation of putative regulatory elements in the
uteroglobin gene promoter. The wild type nucleotide sequence of the
elements is shown, and the observed methylation protection footprints
in vivo are indicated by open triangles. The
filled triangle indicates the observed hypermethylation at position 254. Below the wild type sequence, the upper
strand of the linker-scanner mutants over the respective elements is shown. B, genomic DMS footprinting in vivo after
hCG induction. Endometrial epithelium and liver of pseudopregnant
rabbits were subjected to DMS treatment in vivo.
Piperidine-cleaved genomic DNA was analyzed by ligation-mediated
polymerase chain reaction. Panels show a representative
result from the upper and corresponding lower strand comprising the
distal promoter region from 270 to 200. Similar results were
consistently found in repeated experiments. C, genomic DMS
footprinting after short term estrogen induction. The uterus was
explanted from an oestrus rabbit, and individual pieces were subjected
to synthetic estrogen (diethylstilbestrol; DES) treatment or
vehicle for 4 h. DMS was applied to the luminal surface of the
intact uterus, and the endometrial epithelium cells were analyzed for
resulting DNA modification. Protected guanine residues in the upper
strand are indicated by open triangles (compare with
left part of panel B). On the right of
the gel, a quantitative evaluation of the observed methylation
protection is shown. Bars represent the mean and S.D.
calculated from three independent determinations, an earlier time point
(1/2 h) after the addition of estrogen led to a similar result.
D, methylation protection of the distal promoter region
in vitro. Recombinant ER and Sp1 were incubated with a
radioactively labeled DNA fragment covering the representative promoter
region. Samples were treated with DMS and separated by EMSA. Specific
retarded complexes were analyzed for guanine methylation (19). The
autoradiograms show the upper and lower DNA strand; symbols
are as in panel A.
|
|
The Distal Footprint Is Caused by the Estrogen Receptor, and the
Adjacent Footprint Is Caused by a Member of the Sp Family of
Transcription Factors--
The distal footprint extended from 264 to
252. The pattern of protected guanines resembles an in
vitro footprint formerly described for the ER (7). We verified
that estrogens produced by the ovaries upon hCG stimulation are
responsible for the induced footprint over the ERE by exposing the
explanted uterus from oestrus animals to estrogen treatment. A
footprint was induced when specific ligands of the ER, such as the
synthetic estrogen diethylstilbestrol, were applied. The observed
pattern resembled the footprints from pseudopregnant animals treated
with hCG described above (Fig. 1, compare B and
C). An estrogen-dependent in vivo
footprint over the ERE was detectable as early as 30 min after hormone
treatment (data not shown) and was visible for at least 4 h,
suggesting a direct estrogen response. Similarly to the pairwise
occurrence of footprints in hCG-induced endometrial epithelium,
estrogen treatment of uterus explants elicited the concomitant
occupancy of the ERE and the adjacent GC/GT box (Fig.
1C).
An in vitro approach was chosen to identify the binding
proteins at their respective sites. A DNA fragment encompassing both relevant regions was incubated with nuclear extracts of the endometrial epithelium from hCG-induced animals and subjected to EMSA. Two specifically retarded bands were observed (Fig.
2A, lane 5). The faster migrating band was supershifted by an antibody to ER and, therefore, corresponds to the bound ER (Fig. 2A, lane
1), whereas the slower band was supershifted by an antibody
against Sp1 (Fig. 2A, lane 2; see below).
Moreover, the faster band was competed by an excess of a consensus ERE
oligonucleotide, while the slower band was competed by an
oligonucleotide carrying a binding site for Sp factors (Fig.
2A, lanes 3 and 4, respectively).
Consistently, a mutation in the ERE eliminated the faster band, whereas
a mutation in the GC/GT box eliminated the slower band (Fig.
2A, lanes 7 and 6, respectively).
Similar results were obtained in binding experiments using recombinant
purified Sp1 expressed in vaccinia virus and recombinant human ER
expressed in baculovirus-infected Sf9 cells or in COS-7 cells
(Fig. 2B and data not shown).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 2.
ER and Sp transcription factors bind to the
distal uteroglobin promoter in vitro. A,
specific binding of nuclear proteins from hCG-induced endometrial
epithelium to the uteroglobin promoter fragment comprising the putative
ERE and Sp-binding site ( 304 to 207; lanes 1-5). A gel
retardation experiment was performed with either wild type fragment
(lane 5) or fragments mutated at the Sp-binding site or in
the ERE (lanes 6 and 7, respectively). Extracts
were preincubated with antibodies against ER or Sp1 (lanes 1 and 2, respectively); arrowheads indicate
supershifted antibody-transcription factor complexes. Competition with
an excess of a bona fide ERE or Sp-binding site
oligonucleotide was performed as control (lanes 3 and
4, respectively). B, noncooperative binding of
recombinant human ER and recombinant human Sp1. A fragment comprising
the ERE and Sp-binding site of the uteroglobin promoter (lanes
1-16) and the respective mutants (lanes 17 and
18) were used as in Fig. 2A. Titrations were
performed applying geometrically increasing concentrations of the
corresponding proteins (see Fig. 2C). Recombinant ER was
added as a crude nuclear extract from baculovirus-infected Sf9
cells, and Sp1 was supplied as a vaccinia virus-expressed purified
protein preparation (Promega, Madison, WI). For comparison with
binding to single sites, a gel retardation experiment was performed
under conditions of ternary complex formation (lane 11) but
with the respective mutated oligonucleotides (lanes 17 and
18). Arrows mark the characteristic DNA-protein
complexes, and ER-Sp1 indicates the ternary complex
containing ER, Sp1, and the labeled DNA fragment. Filled
circles denote unspecific or unidentified complexes from ER
preparation; open circles indicate similar bands from the
Sp1 preparation. Bands indicated with open triangles
represent an uncharacterized oligonucleotide species that did not
interfere with binding (see lane 1 and panel A). C, quantitation of the retarded complexes. Lanes
13-16 were quantitated. denotes the fraction of labeled DNA
fragment in the corresponding band. Note the linear functions of the
different DNA-protein complexes from ER concentration.
|
|
The identity of the genomic footprints found in vivo was
further proven by comparison with corresponding footprints generated in vitro. Both recombinant proteins, the
baculovirus-expressed human ER and the vaccinia virus-expressed Sp1,
protected virtually the same guanine residues as mapped in
vivo (Fig. 1D). The same protection pattern was found
when examining the retarded complexes obtained with extracts of induced
endometrial epithelium that were immunologically identified as the
endogenous ER and Sp1 (data not shown). The identity of contacts in
both strands suggests that the genomic footprints originated from
binding of ligand-activated ER and from Sp1.
Functional Synergism between Sp1 and ER--
According to binding
studies in vitro and gene transfer experiments, two
additional putative Sp-binding sites in the uteroglobin promoter have
been proposed (9, 29) (Fig. 1A). To reveal the functional
significance of the various Sp-binding sites, we performed transient
transfection experiments in primary epithelial cells from the
endometrium. We selected linker-scanning mutations that affect Sp
factor binding to the individual GC/GT boxes (9, 29) (Fig.
1A). The wild type uteroglobin gene promoter fragment spanning from 395 to +14 conferred moderate estrogen inducibility to
the reporter (Fig. 3A,
line 1), in accordance with the estrogen induction of
uteroglobin transcription observed in intact animals (5). Mutation of
the ERE completely abolished induction, confirming its function as a
response element (Fig. 3A, line 2). Unexpectedly, mutation of the GC/GT box adjacent to the ERE drastically reduced estrogen induction (Fig. 3A, line 3), whereas
mutations of the more promoter-proximal GC/GT boxes, at 195 and at
65, did not reduce estrogen induction but consistently resulted in
slightly higher induction (Fig. 3A, lines 4 and
5, respectively). Combination of these individual
mutants completely abolished estrogen induction (Fig. 3A,
lines 6-8). This experiment demonstrates that
estrogen-activated transcription requires not only binding of the
activated receptor to its response element but also a synergistic
interaction with another unrelated transcription factor, namely one of
the Sp factors bound to the adjacent GC/GT box. Interestingly, the
basal transcription rate was differently affected by these mutations.
Mutation in the GC/GT box at 65 led to a strong decrease in basal
activity, whereas the two more distal GC/GT boxes exhibited weaker
effects, suggesting a differential role of these sites for basal and
activated transcription.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Modulation of estrogen induction by Sp
transcription factor binding to the uteroglobin promoter. A,
Sp-binding sites in the uteroglobin promoter differentially affect
estrogen induction. Endometrial primary cells from pseudopregnant
rabbits were subjected to transient transfection with reporter plasmids
comprising either wild type or linker-scanner mutants over putative
Sp-binding sites and over the ERE on the uteroglobin promoter. Relative
reporter gene activity was calculated after normalization to
RSV- -galactosidase co-expression level, and estrogen induction was
compared with the respective basal level (in the absence of estrogens).
B, differential effect of co-expressed Sp1 or Sp3 on
estrogen inducibility of the uteroglobin promoter in transiently
transfected SL2 cells. 5 µg of 395UGLuc reporter plasmid was
transfected together with expression vectors for Oct1, human ER, and
either Sp1 or Sp3. Subsaturating amounts of plasmids were used to avoid
competition for limited factors (20): 10 ng of pPacOct, 200 ng of
pPacER, and 10 ng of pPacSp1 or pPacSp3 per 60-mm dish. Similar results were obtained without co-expressed Oct1.
|
|
Since the Sp family of transcription factors includes several members
with similar affinities for GC/GT boxes (8, 15, 20, 29), we performed
co-transfection experiments with ER in SL2 insect cells, which are
devoid of endogenous Sp factors (14). The co-transfected ER alone
conferred only weak estrogen induction to a reporter gene driven by the
uteroglobin promoter; but estrogen induction was significantly enhanced
by co-expression of Sp1, whereas a comparable co-expression of Sp3 had
no such effect (Fig. 3B). Since Sp1 and Sp3 were expressed
at similar levels in insect cells (20) and Sp1 is the most abundant
GC/GT box binding activity in nuclear extracts of endometrial tissue (Fig. 2A, compare lanes 2 and 5), we
tentatively conclude that Sp1 participates in the
estrogen-dependent activation of the uteroglobin gene. The
contribution of other GC/GT box-binding factors, such as Sp4 or BTEB
(30), in the tissue-specific activation of the gene was not tested,
since these proteins were not detectable in the tissue extracts by EMSA
(8) (Fig. 2A).
ER and Sp1 Bind to the Adjacent Binding Sites Simultaneously but
Not Cooperatively--
The recruitment of Sp1 to its binding site
triggered by the binding of the liganded ER could be due to cooperative
DNA binding of the two factors. To test this hypothesis, we performed a
titration experiment with the recombinant human ER and Sp1 proteins and a DNA fragment comprising the ERE and the adjacent GC/GT box. In the
presence of sufficiently high concentrations of both factors, a ternary
complex containing ERE and Sp1 was observed (Fig. 2B, lanes 8 and 11-16), as verified by methylation
protection (data not shown). A similar gel retardation experiment was
performed with DNA fragments mutated in either the ERE or the GT/GC
box. As expected, the retarded band corresponding to the mutated site was not visible, and no ternary complex was detected (Fig.
2B, lanes 17 and 18). A quantitation
of the different DNA-bound proteins as resolved by EMSA (Fig.
2B, lanes 13-16), reveals a linear function between the amount of added ER and the appearance of the ternary complex (Fig. 2C). These data exclude a significant
cooperativity in binding of ER and Sp1 to the corresponding region in
the promoter in vitro.
The Nucleoprotein Organization of the Promoter Changes upon Hormone
Induction--
An alternative explanation for the simultaneous binding
of ER and Sp1 in vivo would be a hormone-induced alteration
in chromatin structure, which could facilitate Sp1 binding. To assess
this possibility, we measured the sensitivity of nuclear chromosomal DNA toward nucleolytic agents like DNase I or methidiumpropyl-EDTA. In
nuclei treated with DNase I, already at the lowest enzyme concentration used, a narrow hypersensitive site was found at position 80
exclusively in the endometrial epithelium of hormonally induced animals
(Fig. 4A). The same region was
also hypersensitive toward methidiumpropyl-EDTA (data not shown). Thus
transcriptional activation of the uteroglobin gene promoter is
accompanied by an alteration of the nucleoprotein organization as
indicated by the preferential accessibility toward nucleolytic agents
at a precise position of the promoter.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 4.
Hormonal induction of a DNase
I-hypersensitive site over the uteroglobin promoter in endometrial
epithelium. DNase I cleavage sites over the promoter region were
mapped by indirect end-labeling analysis of genomic DNA extracted from
the indicated tissues. Nuclei were treated with increasing
concentrations of DNase I. Genomic DNA from untreated nuclei was taken
as control. Radioactively labeled 100-base pair ladder marker DNA (Life
Technologies) served as standard. Fragment length (in base pairs)
is indicated by open circles. The arrowhead
denotes the position of the DNase I hypersensitivity on the uteroglobin
promoter.
|
|
 |
DISCUSSION |
Both the ERE and the Adjacent GC/GT Box Are Essential for Estrogen
Induction--
DNA regulatory elements can be identified in
transfection experiments in cell culture, but the ultimate definition
of sequences involved in the regulation of a particular gene can only
be accomplished by studies in the intact tissue or even in the animal.
One way to approach this goal is to analyze the regulatory regions of DNA using genomic footprinting techniques to identify sites that are
occupied in vivo under physiologically relevant conditions (28). This type of experiment has usually been performed with cell
lines in culture, with the well known limitations imposed by
immortalization and artificial culture conditions. Here, we report the
molecular analysis of steroid hormone effects in the native endometrial
epithelium performed in an organ explant and applied to the rabbit
uteroglobin gene. This methodology also allows us to monitor the
pharmacological effects of related therapeutic agents in the complex
background of the intact animal. The predictions derived from these
studies have been experimentally tested via gene transfer in a
homogenous and nearly authentic cellular system, i.e.
primary cells from the endometrial epithelium.
Previous gene transfer experiments led to the independent
identification of a noncanonical ERE and several GC/GT boxes in the
rabbit uteroglobin promoter, but the contribution of these elements to
gene regulation was unclear since the experiments were carried out in
cells not expressing the endogenous uteroglobin gene (7, 9). In
particular, it was not known whether the GC/GT elements participate in
hormonal induction of the uteroglobin gene. The results of genomic
footprinting experiments in the endometrial epithelium in
situ demonstrate a selective behavior of the different GC/GT
boxes, namely the simultaneous occupancy of the ERE and only the
adjacent GC/GT box following induction of uteroglobin gene expression
during early pseudopregnancy. A similar pattern was observed when
animals were treated only with estrogens, although the extent of the
observed changes was less pronounced, probably reflecting cooperative
hormonal effects throughout early pseudopregnancy. Altogether, these
findings suggest a permissive role for the liganded ER in the occupancy
of the adjacent GC/GT box. Binding experiments with nuclear extracts
from induced endometrial cells and with recombinant purified proteins
suggest that the factors responsible for the observed in
vivo footprints are the ER and members of the Sp family of
transcription factors.
ER and Sp1 Synergize Functionally but Do Not Bind Cooperatively to
the Uteroglobin Promoter DNA--
In addition to the ERE, the
integrity of the adjacent GC/GT box was essential for estrogen
induction in primary endometrial cells. In transfection experiments in
insect cells, which lack Sp factors, ER alone was insufficient for
estrogen-dependent induction of the uteroglobin promoter.
Since Sp1 was able to transcriptionally synergize with ER, while Sp3 is
virtually inactive and represents only a minor fraction of GC/GT
box-binding protein in endometrial epithelium extracts, we assume that
Sp1 is the protein mediating the synergistic occupancy of ERE and GC/GT
box. Sp3 has been shown to contain an inhibitory domain that represses
transactivation mediated by Sp1 (15). Therefore, the possibility of
modulating the estrogen response by changes in the cellular level of
Sp3 relative to Sp1 should be considered (31).
The simultaneous occupancy of the adjacent ERE and GC/GT box could be
due to protein-protein interactions, which would imply cooperative
binding of the two proteins to their respective sites. However,
although ER and Sp1 can bind to a promoter fragment simultaneously, quantitative binding experiments do not reveal a significant binding cooperativity in vitro.
Molecular Mechanism of the Synergism between ER and Sp1--
Other
factors could be involved in synergistic binding of ER and Sp1.
Co-activators, such as CBP/p300, have been suggested to participate in
Sp1 and ER transactivation and could therefore mediate, directly or
indirectly, their synergism (32). Such multiple interactions between
regulatory proteins could be difficult to reproduce in cell-free
binding reactions, since the concentration of some partners in crude
nuclear extracts might be limiting.
Multiple interactions of ER and Sp1 with components of the basal
transcription machinery, such as TATA box binding protein-associated proteins, have been described (33-35), which could mediate the functional synergism (36). Their particular role in synergistic recruitment of the transcriptional preinitiation complex could be
investigated in reconstituted in vitro transcribing
systems.
An alternative explanation could involve the chromatin context of the
DNA template. It is conceivable that ER and Sp1 do synergize for DNA
binding on chromatin, although they do not synergize on free DNA, a
behavior that has been described for other factors (37, 38).
Experiments with nucleosomes assembled on uteroglobin promoter DNA
would be required to clarify this issue.
Finally, hormone-dependent chromatin remodeling could
possibly explain the observed synergism. Binding of ligand-activated ER
to the uteroglobin ERE in chromatin could induce a change in the
chromatin structure required for entry or access of Sp1 to the
promoter. This mechanism is supported by the appearance of a
hormone-inducible DNase I-hypersensitive site in the active promoter
chromatin. A similar mechanism has been proposed for the
glucocorticoid- or progestin-induced binding of the ubiquitous transcription factor NF1 to the murine mammary tumor virus promoter (17, 39, 40). To test this hypothesis, further knowledge about the
nucleosomal organization of the uteroglobin promoter is required.
A similar hormone-dependent binding of sequence-specific
transcription factors to the vicinity of a steroid hormone-responsive element has been observed for the estrogen-inducible apo-very low
density lipoprotein II promoter (41-43), the glucocorticoid-inducible tyrosine aminotransferase gene (44), and the glucocorticoid- or
progesterone-inducible murine mammary tumor virus promoter (39). Thus,
hormone-dependent recruitment of ubiquitous transcription factors to nearby and topologically restricted sites may be a crucial
mechanism of hormonal gene regulation (45-49).
 |
ACKNOWLEDGEMENTS |
We thank L. Klein-Hittpaß (Essen) and
G. L. Greene (Chicago) for the H222 antibody; T. Petri and W.-D.
Schleuning (Schering AG, Berlin) for Sf9 cells infected with
baculovirus expressing the human ER; G. Suske and his team for SL2 cell
expression plasmids, antibody to Sp1, and helpful discussions; and
A. E. Wakeling (Zeneca) for the generous gift of anti-estrogen ICI
164.384. We further thank J. Neulen (Freiburg) for advice
concerning the preparation of epithelial cells from the endometrium,
H. M. Beier (Aachen), and C. Hegele-Hartung (Schering AG) for
advice on the hormonal treatment of the rabbit. The experimental work
was supported by grants from the DFG and the FCI.
 |
FOOTNOTES |
*
This work was supported by the Deutsche
Forschungsgemeinschaft, the European Union, and the Fonds der
Chemischen Industrie.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Dept. of Medicine, University of California San
Diego, 9500 Gilman Dr., CMM Room 345, La Jolla, CA 92093-0648.
§
To whom correspondence should be addressed. Tel.: 49-6421-28-62-86;
Fax: 49-6421-28-53-98; E-mail: beato{at}imt.uni-marburg.de.
1
The abbreviations used are: ERE,
estrogen-responsive element; ER, estrogen receptor; DMS, dimethyl
sulfate; EMSA, electrophoretic mobility shift analysis; hCG, human
chorionic gonadotropin.
 |
REFERENCES |
-
Beato, M.,
Herrlich, P.,
and Schütz, G.
(1995)
Cell
83,
851-857[CrossRef][Medline]
[Order article via Infotrieve]
-
Felsenfeld, G.,
Boyes, J.,
Chung, J.,
Clark, D.,
and Studitsky, V.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9384-9388[Abstract/Free Full Text]
-
Beier, H. M.
(1968)
Biochim. Biophys. Acat.
160,
289-291
-
Krishnan, R. S.,
and Daniel, J. C. J.
(1967)
Science
158,
490-492[Abstract/Free Full Text]
-
Müller, H.,
and Beato, M.
(1980)
Eur. J. Biochem.
112,
235-241[Medline]
[Order article via Infotrieve]
-
Jantzen, C.,
Fritton, H. P.,
Igo-Kemenes, T.,
Espel, E.,
Janich, S.,
Cato, A. C. B.,
Mugele, K.,
Beato, M.
(1987)
Nucleic Acids Res.
15,
4535-4552[Abstract/Free Full Text]
-
Slater, E. P.,
Redeuilh, G.,
Theis, K.,
Suske, G.,
and Beato, M.
(1990)
Mol. Endocrinol.
4,
604-610[Abstract/Free Full Text]
-
Hagen, G.,
Muller, S.,
Beato, M.,
and Suske, G.
(1992)
Nucleic Acids Res.
20,
5519-5525[Abstract/Free Full Text]
-
Suske, G.,
Lorenz, W.,
Klug, J.,
Gazdar, A. F.,
Beato, M.
(1992)
Gene Expr.
2,
339-352[Medline]
[Order article via Infotrieve]
-
Nordeen, S. K.
(1988)
BioTechniques
6,
454-457 [Medline]
[Order article via Infotrieve]
-
Barettino, D.,
Feigenbutz, M.,
Valcarcel, R.,
and Stunnenberg, H. G.
(1994)
Nucleic Acids Res.
22,
541-542[Free Full Text]
-
Sturm, R. A.,
Das, G.,
and Herr, W.
(1988)
Genes Dev.
12,
1582-1599
-
Tora, L.,
Mullick, A.,
Metzger, D.,
Ponglikitmongkol, M.,
Park, I.,
and Chambon, P.
(1989)
EMBO J.
8,
1981-1986[Medline]
[Order article via Infotrieve]
-
Courey, A. J.,
and Tjian, R.
(1988)
Cell
55,
887-898[CrossRef][Medline]
[Order article via Infotrieve]
-
Dennig, J.,
Beato, M.,
and Suske, G.
(1996)
EMBO J.
15,
5659-5667[Medline]
[Order article via Infotrieve]
-
Pfeifer, G. P.,
Steigerwald, S.,
Mueller, P. R.,
Riggs, A. D.
(1989)
Science
246,
810-813[Abstract/Free Full Text]
-
Truss, M.,
Bartsch, J.,
Schelbert, A.,
Haché, R. J. G.,
Beato, M.
(1995)
EMBO J.
14,
1737-1751[Medline]
[Order article via Infotrieve]
-
Andrews, N. C.,
and Faller, D. V.
(1991)
Nucleic Acids Res.
19,
2499[Free Full Text]
-
Truss, M.,
Chalepakis, G.,
Slater, E. P.,
Mader, S.,
Beato, M.
(1991)
Mol. Cell. Biol.
11,
3247-3258[Abstract/Free Full Text]
-
Hagen, G.,
Müller, S.,
Beato, M.,
and Suske, G.
(1994)
EMBO J.
13,
3843-3851[Medline]
[Order article via Infotrieve]
-
Greene, G. L.,
Sobel, N. B.,
King, W. J.,
Jensen, E. V.
(1984)
J. Steroid Biochem.
20,
51-56[CrossRef][Medline]
[Order article via Infotrieve]
-
Schauer, M.,
Chalepakis, G.,
Willmann, T.,
and Beato, M.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1123-1127[Abstract/Free Full Text]
-
DiNocera, P. P.,
and Dawid, I. B.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
7095-7098[Abstract/Free Full Text]
-
Bondy, K. L.,
and Zacharewski, T. R.
(1993)
Nucleic Acids Res.
21,
5277-5278[Free Full Text]
-
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Saffer, J. D.,
Jackson, S. P.,
and Thurston, S. J.
(1990)
Genes Dev.
4,
659-666[Abstract/Free Full Text]
-
Chen, C.,
and Okayama, H.
(1987)
Mol. Cell. Biol.
7,
2745-2752[Abstract/Free Full Text]
-
Church, G. M.,
and Gilbert, W. C.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
1991-1995[Abstract/Free Full Text]
-
Dennig, J.,
Hagen, G.,
Beato, M.,
and Suske, G.
(1995)
J. Biol. Chem.
270,
12737-12744[Abstract/Free Full Text]
-
Sogawa, K.,
Imataka, H.,
Yamasaki, Y.,
Kusume, H.,
Abe, H.,
and Fujiikuriyama, Y.
(1993)
Nucleic Acids Res.
21,
1527-1532[Abstract/Free Full Text]
-
Saceda, M.,
Grunt, T. W.,
Colomer, R.,
Lippman, M. E.,
Lupu, R.,
Martin, M. B.
(1996)
Endocrinology
137,
4322-4330[Abstract]
-
Hanstein, B.,
Eckner, R.,
DiRenzo, J.,
Halachmi, S.,
Liu, H.,
Searcy, B.,
Kurokawa, R.,
and Brown, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
11540-11545[Abstract/Free Full Text]
-
Hoey, T.,
Weinzierl, R. O. J.,
Gill, G.,
Chen, J. L.,
Dynlacht, B. D.,
Tjian, R.
(1993)
Cell
72,
247-260[CrossRef][Medline]
[Order article via Infotrieve]
-
Gill, G.,
Pascal, E.,
Tseng, Z. H.,
Tjian, R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
192-196[Abstract/Free Full Text]
-
Jacq, X.,
Brou, C.,
Lutz, Y.,
Davidson, I.,
Chambon, P.,
and Tora, L.
(1994)
Cell
79,
107-117[CrossRef][Medline]
[Order article via Infotrieve]
-
Sauer, F.,
Hansen, S. K.,
and Tjian, R.
(1995)
Science
270,
1783-1788[Abstract/Free Full Text]
-
Polach, K. J.,
and Widom, J.
(1995)
J. Mol. Biol.
254,
130-149[CrossRef][Medline]
[Order article via Infotrieve]
-
Adams, C. C.,
and Workman, J. L.
(1995)
Mol. Cell. Biol.
15,
1405-1421[Abstract]
-
Cordingley, M. G.,
Riegel, A. T.,
and Hager, G. L.
(1987)
Cell
48,
261-270[CrossRef][Medline]
[Order article via Infotrieve]
-
Eisfeld, K.,
Candau, R.,
Truss, M.,
and Beato, M.
(1997)
Nucleic Acids Res.
25,
3733-3742[Abstract/Free Full Text]
-
Wijnholds, J.,
Philipsen, J. N. J.,
AB, G.
(1988)
EMBO J.
7,
2757-2762[Medline]
[Order article via Infotrieve]
-
Kok, K.,
Snippe, L., AB, G.,
and Gruber, M.
(1985)
Nucleic Acids Res.
13,
5189-5202[Abstract/Free Full Text]
-
Wijnholds, J.,
Muller, E.,
and Ab, G.
(1991)
Nucleic Acids Res.
19,
33-41[Abstract/Free Full Text]
-
Becker, P. B.,
Gloss, B.,
Schmid, W.,
Strähle, U.,
and Schütz, G.
(1986)
Nature
324,
686-688[CrossRef][Medline]
[Order article via Infotrieve]
-
Schippers, I. J.,
Kloppenburg, M.,
van Waardenburg, R.,
AB, G.
(1994)
Eur. J. Biochem.
221,
43-51[Medline]
[Order article via Infotrieve]
-
Strähle, U.,
Schmid, W.,
and Schütz, G.
(1988)
EMBO J.
7,
3389-3395[Medline]
[Order article via Infotrieve]
-
Eddy, E. M.,
Washburn, T. F.,
Bunch, D. O.,
Goulding, E. H.,
Gladen, B. C.,
Lubahn, D. B.,
Korach, K. S.
(1996)
Endocrinology
137,
4796-4805[Abstract]
-
Schüle, R.,
Müller, M.,
Otsuka-Murakami, H.,
and Renkawitz, R.
(1988)
Nature
332,
87-90[CrossRef][Medline]
[Order article via Infotrieve]
-
Schüle, R.,
Muller, M.,
Otsuka-Murakami, H.,
and Renkawitz, R.
(1988)
Science
242,
1418-1420[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Safe and K. Kim
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways
J. Mol. Endocrinol.,
November 1, 2008;
41(5):
263 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Gao, S. Falt, A. Sandelin, J.-A. Gustafsson, and K. Dahlman-Wright
Genome-Wide Identification of Estrogen Receptor {alpha}-Binding Sites in Mouse Liver
Mol. Endocrinol.,
January 1, 2008;
22(1):
10 - 22.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Mukherjee, Z. Zhang, and B. S. Chilton
Uteroglobin: A Steroid-Inducible Immunomodulatory Protein That Founded the Secretoglobin Superfamily
Endocr. Rev.,
December 1, 2007;
28(7):
707 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Velarde, Z. Zeng, J. R. McQuown, F. A. Simmen, and R. C. M. Simmen
Kruppel-Like Factor 9 Is a Negative Regulator of Ligand-Dependent Estrogen Receptor {alpha} Signaling in Ishikawa Endometrial Adenocarcinoma Cells
Mol. Endocrinol.,
December 1, 2007;
21(12):
2988 - 3001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M L Panno, L Mauro, S Marsico, D Bellizzi, P Rizza, C Morelli, M Salerno, F Giordano, and S Ando'
Evidence that the mouse insulin receptor substrate-1 belongs to the gene family on which the promoter is activated by estrogen receptor {alpha} through its interaction with Sp1
J. Mol. Endocrinol.,
February 1, 2006;
36(1):
91 - 105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Vallejo, C. Ballare, J. Lino Baranao, M. Beato, and P. Saragueta
Progestin Activation of Nongenomic Pathways via Cross Talk of Progesterone Receptor with Estrogen Receptor {beta} Induces Proliferation of Endometrial Stromal Cells
Mol. Endocrinol.,
December 1, 2005;
19(12):
3023 - 3037.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Xiao, A. Mirwald, M. Papaioannou, A. Baniahmad, and J. Klug
Secretoglobin 2A1 Is under Selective Androgen Control Mediated by a Peculiar Binding Site for Sp Family Transcription Factors
Mol. Endocrinol.,
December 1, 2005;
19(12):
2964 - 2978.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y-L Zhao, W-D Han, Q Li, Y-M Mu, X-C Lu, L Yu, H-J Song, X Li, J-M Lu, and C-Y Pan
Mechanism of transcriptional regulation of LRP16 gene expression by 17-{beta} estradiol in MCF-7 human breast cancer cells
J. Mol. Endocrinol.,
February 1, 2005;
34(1):
77 - 89.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Schultz, L. N. Petz, and A. M. Nardulli
Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors {alpha} and {beta}
J. Biol. Chem.,
January 7, 2005;
280(1):
347 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fujita, M. Kajita, P. Taysavang, and P. A. Wade
Hormonal Regulation of Metastasis-Associated Protein 3 Transcription in Breast Cancer Cells
Mol. Endocrinol.,
December 1, 2004;
18(12):
2937 - 2949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. O'Lone, M. C. Frith, E. K. Karlsson, and U. Hansen
Genomic Targets of Nuclear Estrogen Receptors
Mol. Endocrinol.,
August 1, 2004;
18(8):
1859 - 1875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hewetson and B. S. Chilton
An Sp1-NF-Y/Progesterone Receptor DNA Binding-dependent Mechanism Regulates Progesterone-induced Transcriptional Activation of the Rabbit RUSH/SMARCA3 Gene
J. Biol. Chem.,
October 10, 2003;
278(41):
40177 - 40185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-H. Li and D. E. Ong
Cellular Retinoic Acid-binding Protein II Gene Expression Is Directly Induced by Estrogen, but Not Retinoic Acid, in Rat Uterus
J. Biol. Chem.,
September 12, 2003;
278(37):
35819 - 35825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Otsuki, H. Gao, K. Dahlman-Wright, C. Ohlsson, N. Eguchi, Y. Urade, and J.-A. Gustafsson
Specific Regulation of Lipocalin-Type Prostaglandin D Synthase in Mouse Heart by Estrogen Receptor {beta}
Mol. Endocrinol.,
September 1, 2003;
17(9):
1844 - 1855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. N. Petz, Y. S. Ziegler, M. A. Loven, and A. M. Nardulli
Estrogen Receptor {alpha} and Activating Protein-1 Mediate Estrogen Responsiveness of the Progesterone Receptor Gene in MCF-7 Breast Cancer Cells
Endocrinology,
December 1, 2002;
143(12):
4583 - 4591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Krikun and C. J. Lockwood
Steroid Hormones, Endometrial Gene Regulation and the Sp1 Family of Proteins
Reproductive Sciences,
November 1, 2002;
9(6):
329 - 334.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Klinge
Estrogen receptor interaction with estrogen response elements
Nucleic Acids Res.,
July 15, 2001;
29(14):
2905 - 2919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. N. Petz and A. M. Nardulli
Sp1 Binding Sites and An Estrogen Response Element Half-Site Are Involved in Regulation of the Human Progesterone Receptor A Promoter
Mol. Endocrinol.,
July 1, 2000;
14(7):
972 - 985.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Lu, G. Jenster, and D. E. Epner
Androgen Induction of Cyclin-Dependent Kinase Inhibitor p21 Gene: Role of Androgen Receptor and Transcription Factor Sp1 Complex
Mol. Endocrinol.,
May 1, 2000;
14(5):
753 - 760.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
L. Dong, W. Wang, F. Wang, M. Stoner, J. C. Reed, M. Harigai, I. Samudio, M. P. Kladde, C. Vyhlidal, and S. Safe
Mechanisms of Transcriptional Activation of bcl-2 Gene Expression by 17beta -Estradiol in Breast Cancer Cells
J. Biol. Chem.,
November 5, 1999;
274(45):
32099 - 32107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Di Croce, G. P. Vicent, A. Pecci, G. Bruscalupi, A. Trentalance, and M. Beato
The Promoter of the Rat 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Gene Contains a Tissue-Specific Estrogen-Responsive Region
Mol. Endocrinol.,
August 1, 1999;
13(8):
1225 - 1236.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
W. Wang, L. Dong, B. Saville, and S. Safe
Transcriptional Activation of E2F1 Gene Expression by 17{beta}-Estradiol in MCF-7 Cells Is Regulated by NF-Y-Sp1/Estrogen Receptor Interactions
Mol. Endocrinol.,
August 1, 1999;
13(8):
1373 - 1387.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. C. M. Simmen, T. E. Chung, H. Imataka, F. J. Michel, L. Badinga, and F. A. Simmen
Trans-Activation Functions of the Sp-Related Nuclear Factor, Basic Transcription Element-Binding Protein, and Progesterone Receptor in Endometrial Epithelial Cells
Endocrinology,
June 1, 1999;
140(6):
2517 - 2525.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Scholz, M. Truss, and M. Beato
Hormone-dependent Recruitment of NF-Y to the Uteroglobin Gene Enhancer Associated with Chromatin Remodeling in Rabbit Endometrial Epithelium
J. Biol. Chem.,
February 12, 1999;
274(7):
4017 - 4026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ray, H. Schatten, and B. K. Ray
Activation of Sp1 and Its Functional Co-operation with Serum Amyloid A-activating Sequence Binding Factor in Synoviocyte Cells Trigger Synergistic Action of Interleukin-1 and Interleukin-6 in Serum Amyloid A Gene Expression
J. Biol. Chem.,
February 12, 1999;
274(7):
4300 - 4308.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|